Evidence map›Paper›PMID 30408040›Full record

ArticlePloS one2018

Decreased GPIHBP1 protein levels in visceral adipose tissue partly underlie the hypertriglyceridemic phenotype in insulin resistance.

R Preethi Surendran, Shanti D Udayyapan, Mercedes Clemente-Postigo, Stefan R Havik, Alinda W M Schimmel, Fransisco Tinahones, Max Nieuwdorp, Geesje M Dallinga-Thie

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

R Preethi SurendranDepartment of Experimental Vascular Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands.
Shanti D UdayyapanDepartment of Experimental Vascular Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands.
Mercedes Clemente-PostigoUnidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga (Virgen de la Victoria)/Universidad de Malaga, Malaga, Spain.
Stefan R HavikDepartment of Experimental Vascular Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands.
Alinda W M SchimmelDepartment of Experimental Vascular Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands.
Fransisco TinahonesUnidad de Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga (Virgen de la Victoria)/Universidad de Malaga, Malaga, Spain.
Max NieuwdorpDepartment of Vascular Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands.
Geesje M Dallinga-ThieDepartment of Experimental Vascular Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands.ORCID 0000-0001-5412-5923
Amsterdam University Medical Centers · NLCentro de Investigación Biomédica en Red · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GPIHBP1 is a protein localized at the endothelial cell surface that facilitates triglyceride (TG) lipolysis by binding lipoprotein lipase (LPL). Whether Glycosyl Phosphatidyl Inositol high density lipoprotein binding protein 1 (GPIHBP1) function is impaired and may underlie the hyperTG phenotype observed in type 2 diabetes is not yet established. To elucidate the mechanism underlying impaired TG homeostasis in insulin resistance state we studied the effect of insulin on GPIHBP1 protein expression in human microvascular endothelial cells (HMVEC) under flow conditions. Next, we assessed visceral adipose tissue GPIHBP1 protein expression in type 2 diabetes Lepr db/db mouse model as well as in subjects with ranging levels of insulin resistance. We report that insulin reduces the expression of GPIHBP1 protein in HMVECs. Furthermore, GPIHBP1 protein expression in visceral adipose tissue in Lepr db/db mice is significantly reduced as is the active monomeric form of GPIHBP1 as compared to Leprdb/m mice. A similar decrease in GPIHBP1 protein was observed in subjects with increased body weight. GPIHBP1 protein expression was negatively associated with insulin and HOMA-IR. In conclusion, our data suggest that decreased GPIHBP1 availability in insulin resistant state may hamper peripheral lipolysis capacity.

Indexed as

AnimalsDiabetes Mellitus, Type 2Disease Models, AnimalEndothelial CellsGene Expression RegulationHumansHypertriglyceridemiaInsulinInsulin ResistanceIntra-Abdominal FatLipolysisLipoprotein LipaseMiceMice, Inbred NODMicrovesselsReceptors, LipoproteinGPIHBP1 protein, humanInsulinLipoprotein LipaseReceptors, LipoproteinTriglycerides

Identifiers

PMID30408040
PMCPMC6224034
OpenAlexW2899526828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.